Panel Discussion | Is It Feasible to Conduct Meaningful Randomized Clinical Trials for Cardiogenic Shock in 2026 and Beyond?

Sunday, March 8, 2026

11:41 AM - 12:05 PM EST

Location: International Ballroom East

Moderator(s)

Jacob Eifer Møller, MD

Consultant
Rigshospitalet Copenhagen Denmark

Disclosure(s): Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Magenta,: Consulting Fees (e.g., advisory boards) (Ongoing)
Pooja Swamy, MD

Interventional Cardiologist
MYCARDIOLOGIST, Miami, Florida , California, United States

Disclosure(s): No financial relationships to disclose
Alexander G. Truesdell, MD

Interventional Cardiology
Virginia Heart / Inova Schar Heart and Vascular
McLean, Virginia, United States

Disclosure(s): Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chiesi: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Zoll: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Panel Discussant(s)

Daniel Burkhoff, MD, PhD

Director: Heart Failure, Hemodynamics and MCS Research
Cardiovascular Research Foundation
New York, New York, United States

Disclosure(s): Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
Maya Guglin, MD

Director of Heart Failure/Transplant/MCS
Rutgers University
Indianapolis, Indiana, United States

Disclosure(s): No financial relationships to disclose
Ben Kenigsberg, MD

Co-Director Medical Cardiovascular ICU
MedStar Washington Hospital Center

Disclosure(s): No financial relationships to disclose
Ajar Kochar, MD, MHS

Program Director
Brigham and Women's Hospital/Harvard Medical School
CHESTNUT HILL, Massachusetts, United States

Disclosure(s): Abbott Vascular, Abiomed, Philips, Penumbra, shockwave and Medtronic.: Grant/Research Support (Ongoing); Abiomed Inc: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Rampart Medical: Grant/Research Support (Ongoing)
David A. Morrow, MD

Director, Levine Cardiac Intensive Care Unit
Brigham and Women's Hospital

Disclosure(s): 4TEEN4: Grant/Research Support (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Abiomed: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anthos Therapeutics: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Daiichi Sankyo: Grant/Research Support (Ongoing); Merck & Co.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Roche Diagnostics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
Mauro Moscucci, MD, MBA, MPH

Medical Officer
Food and Drug Administration, Center for Devices and Radiological Health, Maryland, United States

Disclosure(s): No financial relationships to disclose
Holger Thiele, MD

Head of department
Heart Center Leipzig
Leipzig, Sachsen, Germany

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Jacob Eifer Møller, MD: Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Magenta,: Consulting Fees (e.g., advisory boards) (Ongoing)

Pooja Swamy, MD: No financial relationships to disclose

Alexander G. Truesdell, MD: Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chiesi: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Zoll: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Daniel Burkhoff, MD, PhD: Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Maya Guglin, MD: No financial relationships to disclose

Ben Kenigsberg, MD: No financial relationships to disclose

Ajar Kochar, MD, MHS: Abbott Vascular, Abiomed, Philips, Penumbra, shockwave and Medtronic.: Grant/Research Support (Ongoing); Abiomed Inc: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Rampart Medical: Grant/Research Support (Ongoing)

David A. Morrow, MD: 4TEEN4: Grant/Research Support (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Abiomed: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anthos Therapeutics: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Daiichi Sankyo: Grant/Research Support (Ongoing); Merck & Co.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Roche Diagnostics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Mauro Moscucci, MD, MBA, MPH: No financial relationships to disclose

Holger Thiele, MD: No financial relationships to disclose